{
    "clinical_study": {
        "@rank": "9858", 
        "arm_group": {
            "arm_group_label": "Patients taking tramadol hydrochloride and acetaminophen"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the impact of extended release tramadol\n      hydrochloride (75 mg) and acetaminophen (650 mg) tablets on improvement of pain."
        }, 
        "brief_title": "A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Pain", 
        "detailed_description": {
            "textblock": "This is a multi-center (study conducted at multiple sites), open label (all people know the\n      identity of the intervention), prospective (in which the participants are first identified\n      and then followed forward as time passes), observational study to assess the improvement of\n      pain and health-related quality of life in patients with moderate to severe chronic\n      non-malignant pain. The study will enroll patients who had already filled a prescription for\n      extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg (ULTRACET ER). The\n      study medication will be administered according to local label insert. The study medication\n      will be taken twice daily, 1 to 2 tablets each time, for a maximum of 4 tablets. Safety\n      evaluations for adverse events will be performed throughout the study. The total duration of\n      the study will be approximately of 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with the prescription of ULTRACET ER for the treatment of moderate to severe\n             pain\n\n          -  Complaining of chronic pain for more than 3 months\n\n        Exclusion Criteria:\n\n          -  Patient who had been treated with extended release tramadol hydrochloride (75mg) and\n             acetaminophen (650mg) or strong opioids (eg, morphine, fentanyl, oxycodone,\n             hydromorphone) within the past 4 weeks\n\n          -  Patient with a severe mental disease and with a medical history of hypersensitivity\n             to opioid analgesics\n\n          -  Pregnant females or the females likely to become pregnant during the study period\n\n          -  Patient who had been believed likely to complain of more pain than the real pain he\n             or she is experiencing because of industrial disaster, car insurance, and others\n\n          -  Patients who are contraindicated according to the warnings, precautions and\n             prohibitions regarding extended release tramadol hydrochloride (75mg) and\n             acetaminophen (650mg)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic non-malignant pain taking tramadol hydrochloride and acetaminophen"
            }
        }, 
        "enrollment": {
            "#text": "1065", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819805", 
            "org_study_id": "CR100722", 
            "secondary_id": [
                "TRAMAPPAI4047", 
                "ULTER-KOR-5005"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Patients taking tramadol hydrochloride and acetaminophen", 
            "description": "This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug", 
            "other_name": "ULTRACET ER"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Tramadol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic pain", 
            "Chronic non-malignant pain", 
            "Non-malignant", 
            "Pain", 
            "Extended release tablet", 
            "Tramadol hydrochloride", 
            "Tramadol HCl", 
            "Acetaminophen", 
            "Ultracet ER"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheonan", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chungcheongbuk-Do", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chungju-Si", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi-Do", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hwasun Gun", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kwangiu", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kwangjoo", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyungjoo", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Evaluation of the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol HCl (75mg)/Acetaminophen (650mg) Extended Release Tablet: Multicenter, Open Label, Prospective, Observational Study", 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Korea: Institutional Review Board", 
                "Korea: Food and Drug Administration", 
                "Republic of Korea: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Numerical Rating Scale (NRS) is an 11-point scale to measure the pain intensity and is used by patients to rate their pain from 0 (absence of pain) to 10 (extreme pain). Percentage PID =[(NRS score at baseline - NRS score at Week 12)/NRS score at baseline] X 100.", 
            "measure": "Number of patients with more than 30 percentage reduction in percentage Pain Intensity Difference (PID) from baseline", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Week 1) to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819805"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The KEQ-5D is a validated generic measure of quality of life which usually requires less than 1 minute to complete (eg, the questionnaire may have questions about mobility, self care, usual activities, pain/discomfort and anxiety/depression).", 
                "measure": "Change in scores of Korean version of the EuroQol 5 Dimensional (KEQ-5D) Questionnaire from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "Sleep disturbance due to pain will be measured using a Numeric Rating Scale (NRS): 1 = None, 10 = Complete.", 
                "measure": "The degree of night sleep disturbance due to pain", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "The degree of interference with activity of daily living due to pain will be assessed on a 5-point scale: 1 = No interference, 5 = Great interference. Activity of daily living  means household work performance, etc.", 
                "measure": "The degree of Interference with activity of daily living due to Pain", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "The degree of interference with social life performance due to pain will be measured on a 5-point scale; 1 = No interference, 5 = Great interference. Social activities means interpersonal relationship, going out, working life, etc.", 
                "measure": "The degree of Interference with social activities due to Pain", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "The investigator will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been for a patient, in the judgment of the investigator.", 
                "measure": "The investigator's global assessment of pain treatment", 
                "safety_issue": "No", 
                "time_frame": "Week 4 to Week 12"
            }, 
            {
                "description": "The patient will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been in the judgment of the study patient.", 
                "measure": "The patient's global assessment of pain treatment", 
                "safety_issue": "No", 
                "time_frame": "Week 4 to Week 12"
            }, 
            {
                "measure": "The number of patients who experience adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Week 4 to Week 12"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}